Meningioma - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 83 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Meningioma - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Meningioma - Pipeline Review, H1 2016', provides an overview of the Meningioma pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Meningioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Meningioma and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Meningioma
- The report reviews pipeline therapeutics for Meningioma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Meningioma therapeutics and enlists all their major and minor projects
- The report assesses Meningioma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Meningioma


Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Meningioma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Meningioma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Meningioma Overview 6
Therapeutics Development 7
Pipeline Products for Meningioma - Overview 7
Pipeline Products for Meningioma - Comparative Analysis 8
Meningioma - Therapeutics under Development by Companies 9
Meningioma - Therapeutics under Investigation by Universities/Institutes 10
Meningioma - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Meningioma - Products under Development by Companies 13
Meningioma - Products under Investigation by Universities/Institutes 14
Meningioma - Companies Involved in Therapeutics Development 15
Arno Therapeutics, Inc. 15
Boehringer Ingelheim GmbH 16
e-Therapeutics Plc 17
GlaxoSmithKline Plc 18
Novartis AG 19
Pfizer Inc. 20
Pharma Mar, S.A. 21
Progenics Pharmaceuticals, Inc. 22
Meningioma - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
afatinib dimaleate - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
AR-42 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Edotreotide Labeled Yttrium 90 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ETS-2101 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
GSK-2256098 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
HXR-9 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
pasireotide - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
sunitinib malate - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
trabectedin - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Meningioma - Recent Pipeline Updates 60
Meningioma - Dormant Projects 79
Meningioma - Product Development Milestones 80
Featured News & Press Releases 80
Sep 21, 2015: Enrollment of first patient in a Phase II trabectedin study in brain tumor type called meningioma 80
Jun 07, 2012: Arno Therapeutics Announces Additional Orphan-Drug Designations For AR-42 In Europe 80
Feb 21, 2012: Arno Therapeutics Receives Two Orphan-Drug Designations For AR-42 To Treat Central-Nervous-System Tumors 81
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 82
Disclaimer 83

List of Tables

Number of Products under Development for Meningioma, H1 2016 7
Number of Products under Development for Meningioma - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Products under Investigation by Universities/Institutes, H1 2016 14
Meningioma - Pipeline by Arno Therapeutics, Inc., H1 2016 15
Meningioma - Pipeline by Boehringer Ingelheim GmbH, H1 2016 16
Meningioma - Pipeline by e-Therapeutics Plc, H1 2016 17
Meningioma - Pipeline by GlaxoSmithKline Plc, H1 2016 18
Meningioma - Pipeline by Novartis AG, H1 2016 19
Meningioma - Pipeline by Pfizer Inc., H1 2016 20
Meningioma - Pipeline by Pharma Mar, S.A., H1 2016 21
Meningioma - Pipeline by Progenics Pharmaceuticals, Inc., H1 2016 22
Assessment by Monotherapy Products, H1 2016 23
Number of Products by Stage and Target, H1 2016 25
Number of Products by Stage and Mechanism of Action, H1 2016 27
Number of Products by Stage and Route of Administration, H1 2016 29
Number of Products by Stage and Molecule Type, H1 2016 31
Meningioma Therapeutics - Recent Pipeline Updates, H1 2016 60
Meningioma - Dormant Projects, H1 2016 79